INTRODUCTION
Veterans with Gulf War Illness (GWI) experience chronic symptoms of fatigue, pain, and cognitive difficulty.
1,2 While we do not fully understand the mechanisms underlying these symptoms, [3] [4] [5] [6] we know that GWI is distinct from other disorders which share similar features, such as chronic fatigue syndrome 7, 8 and fibromyalgia. 9 As Veterans from the 1991 Gulf War are aging, other age-related disorders begin to confound our ability to identify GWI and identify underlying mechanisms. 10 Yet Veterans continue to endure substantial physical and mental burdens. 9, 11, 12 GWI shares symptoms with autonomic dysfunction, and autonomic dysfunction has been previously suggested 7, 13, 14 as a potential contributing factor in GWI. It is possible that assessment of autonomic functioning in Veterans with GWI may help us understand either the underlying mechanisms in GWI or offer additional treatments for persistent symptoms.
Mental health comorbidities, prevalent in Veterans with GWI and in combat-deployed Veterans in general, interact with autonomic function as well and need to be taken into account. Anxiety, post-traumatic stress disorder (PTSD), and depression all have a higher prevalence in deployed Veteran populations 11, [15] [16] [17] compared with non-deployed military or civilian populations. Additionally, each of these mental health comorbidities can impact the functioning of the autonomic nervous system resulting in either differences in response to stressors or chronic imbalances in autonomic tone. [18] [19] [20] [21] [22] [23] [24] [25] [26] Furthermore, there is a distinct overlap between some physiological aspects of some mental health conditions (e.g., heart racing, difficulty breathing, trouble sleeping) and symptoms of autonomic dysfunction. Thus, it is potentially difficult to differentiate to what extent these symptoms reflect autonomic symptoms of a psychiatric condition versus autonomic symptoms due to other medical causes, such as GWI.
Our purpose was to characterize the presence of autonomic symptoms within our clinical sample with GWI using the Composite Autonomic Symptom Scale (COMPASS-31). In light of prevalent comorbidities, we also examined autonomic symptoms as they related to the several different mental health conditions mentioned.
MATERIALS AND METHODS

Setting
The War Related Illness and Injury Study Center (WRIISC) at the Veterans Affairs (VA) New Jersey Health Care System is a tertiary evaluation center specializing in post-deployment health, exposure concerns, and medically unexplained symptoms. Veterans are referred by VA clinicians and are evaluated by the WRIISC's multidisciplinary team of practitioners.
Subjects
Veterans were included in the first part of the case series (a chart review) if they were (1) deployed to the Persian Gulf between 1990 and 1991 and (2) were evaluated by the WRIISC between 2011 and 2016 for medically unexplained symptoms. 27 There were no exclusion criteria for the chart review. All Veterans included in the chart review (n = 153) were contacted by letter and follow-up phone call and invited to participate in the follow-up phone interview. Of these, 61 (39.8%) agreed to participate and were enrolled in this arm of the study. Participation involved a 70-minute phone administration of validated questionnaires. Additionally, subjects were asked about current medications. All contact with study subjects, including outreach for participation and administration of questionnaires, was made by the first author, an integrative neuroscientist. The study was carried out in accordance with and approval from the institutional review board of the VA Medical Center. As the study was conducted entirely over the telephone, only verbal consent was obtained. All subjects provided verbal consent prior to participation, in accordance with the Declaration of Helsinki.
Gulf War Illness
The Kansas Questionnaire, used to detect GWI, was developed by Steele 1 and asks questions about military service and physical health. In order to meet the criteria of "GWI" according to Kansas criteria, subjects must meet inclusion criteria for three out of six chronic symptom clusters (pain, cognitive/mood, fatigue, gastrointestinal, skin, respiratory) while also not meeting exclusionary criteria (e.g., diabetes, cancer, chronic infectious disease, serious psychiatric disorder) that might explain the presence of symptoms. Another prevalent method for categorizing GWI was created by the Centers for Disease Control (CDC). To meet the CDC criteria for GWI, subjects must meet two of three symptom clusters (fatigue, pain, cognitive/mood) and there are no exclusionary criteria. Due to differences in the inclusion criteria, it is possible to meet criteria for GWI with one or both definitions. These case definitions are recommended for research purposes by the Institutes of Medicine, 28 but in clinical practice, either definition can be used to inform management of patient symptoms, as suggested by the case definition used in the DoD/ VA Clinical Practice Guideline for the Management of Chronic Multisymptom Illness. 29 Therefore, to increase clinical relevance we included Veterans who met either or both definitions of GWI and excluded Veterans who met neither of these definitions, consistent with the clinical practice guideline. Our final sample for examination included 56 Veterans.
Questionnaires
Autonomic symptoms were measured using the Composite Autonomic Symptom Scale (COMPASS-31), a questionnaire that demonstrates high internal consistency, test-retest reliability, and convergent validity. 30, 31 This instrument has been used by several researchers investigating GWI and other similar disorders. 14, 32, 33 The COMPASS-31 was designed to capture symptoms of autonomic dysfunction across six primary domains (orthostatic, vasomotor, secretomotor, gastrointestinal, bladder, and pupilomotor) and produces domain scores as well as a total score (range 0-100) 30 with higher scores indicating greater autonomic symptom burden. Individual questions within domains inquire about symptom frequency (rarely to almost always), symptom severity (mild to severe), and symptom improvement (much worse to completely gone). Depending on the domain, possible scores in each domain ranged from 6 (vasomotor) to 28 (gastrointestinal). The total score is computed using a weighted equation of all individual domain scores. Because each domain contains a different number of questions and different maximal score, we present the data from each domain as a percent of the total possible score to more easily compare symptoms across domains.
Anxiety was measured using the Beck Anxiety Inventory (BAI), a 21-item validated questionnaire designed to identify probable symptoms of anxiety. 34 Scored on a scale of 0-63, anxiety is categorized as minimal to severe with higher scores indicating more anxiety symptoms. 34 Subjects were categorized as having anxiety symptoms if they had a score of 16 or higher, consistent with a rating of "moderate anxiety" as defined by the authors of the questionnaire. 35 We also looked at two-factor subscale analyses (cognitive versus physical symptoms) of the BAI to examine the relationship between COMPASS-31 scores and different facets of anxiety. 35 Depression was measured using the Patient Health Questionnaire depression scale (PHQ-8). This eight-item questionnaire is widely used as a rapid and effective tool for screening for major depressive disorder. 36 The questionnaire is scored from 0 to 24 with higher scores indicating more symptoms of depression; a score of 10 or more is considered suggestive of major depression. 36 For our study, we used the suggested cut-off threshold of 10 or more as well as a requirement of anhedonia (score of 2 or more on questions 1 or 2) to classify participants as likely having depression. 36 Physical symptom burden was measured using the Patient Health Questionnaire somatization scale (PHQ-15). This is a 15-item questionnaire designed to evaluate the severity of somatic symptoms. 37 Scores range from 0 to 30 and higher scores reflect greater overall physical symptom burden. 38 PTSD was measured using the Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5). This newer version of the PCL has been updated to reflect the new diagnostic criteria established by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition and is a validated instrument designed to identify PTSD within a military population. There are 20 items and higher scores (range 0-80) indicate greater symptom severity. For this questionnaire, PTSD is identified using a cut-off score of 33 or more combined with the presentation of specific symptom clusters as defined by the DSM-5.
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Medication use was measured by asking participants to report all medications they were taking at the time of the phone interview. Following the interview, medications were analyzed by the total number of medications used and by classifying medications into mutually exclusive categories.
Analysis
We used descriptive (mean and standard deviation, frequency/ percentage distributions) and bivariate statistics (Welch's ttests, Pearson Product Moment Correlation Coefficients) to evaluate the relationships present within our sample. Due to our limited sample size, we arbitrarily chose a more stringent alpha (p < 0.01) rather than a conventional one (p < 0.05) to aid in our ability to identify relationships and generate hypotheses. All statistics were conducted using SPSS (IBM, v.24).
RESULTS
Our sample was comprised of males (n = 55, 98%), aged 49.7 (±6.8). The time between evaluation at the WRIISC and the current study was on average 1.8 yr (±1.5). On average, our subjects were taking 8.5 (±6.6) medications [this is made up of prescription medications (7.14 ± 5.74) and supplements (2.14 ± 1.33)]. The most frequent medications reported, taken by at least 40% of Veterans in our sample, were: nutritional supplements (n = 36, 59%), antidepressants (n = 32, 52%), medications for blood pressure and/or cardiovascular conditions (n = 31, 51%), medications to treat allergies (n = 27, 44%), non-steroidal anti-inflammatory drugs (n = 26, 43%), and drugs for gastrointestinal symptoms (n = 25, 41%).
Nearly all of our subjects (n = 50, 89%) met CDC criteria for GWI while 73% (n = 41) met Kansas criteria for GWI. In our sample, those subjects who met CDC criteria and not Kansas criteria did so because of the exclusionary criteria: diabetes (n = 11), cancer (n = 4), stroke (n = 4), chronic infectious disease (n = 3), lupus (n = 3), serious psychiatric (n = 2), and multiple sclerosis (n = 1).
On average, subjects reported PHQ-15 scores of 17.4 (±4.9) and COMPASS-31 scores of 45.6 (±18.3). One-third of our subjects met screening criteria for PTSD, 46% met screening criteria for depression, and 80% met screening criteria for anxiety (see Table I ).
When looking at physical symptom burden (PHQ-15 score) across different mental health groups, there were no differences between subjects screening positive or negative for depression or PTSD, but there were differences in physical symptom burden for subjects screening positive or negative for anxiety. When looking at autonomic symptoms across different mental health groups, there were no differences in autonomic symptoms reported by subjects screening positive or negative for depression or PTSD, but there were differences in autonomic symptoms reported by subjects screening positive or negative for anxiety. Examining the relationship between the COMPASS-31 and the BAI further, we looked at the questions across each questionnaire (see Table II ). As seen in Table II , there is overlap in the questions asked on the physical subdomain of the BAI with questions asked on the COMPASS-31. Using the two-factor model of the BAI, we found that the total score of the COMPASS-31 was strongly correlated with the physical subscale of the BAI (r = 0.638, p < 0.001) while only weakly correlated with the cognitive subscale (r = 0.275, p < 0.05).
DISCUSSION
In our sample of clinical Gulf War veterans with GWI, we saw a substantial report of autonomic symptoms as measured by the COMPASS-31 (mean overall score 45.6 ± 18.3). Generally, subjects meeting Kansas criteria reported fewer symptoms than subjects meeting CDC criteria, consistent with the idea that those subjects meeting Kansas criteria had fewer comorbid health concerns. Our high COMPASS-31 scores are consistent with previously published reports of Veterans with GWI, 14 patients with fibromyalgia, 40 and patients with small fiber polyneuropathy. 31 While there is consistent support suggesting that the COMPASS-31 correlates well with other self-reported measures of disease burden across many groups with autonomic dysfunction, [41] [42] [43] [44] there is inconsistent support for the COMPASS-31 correlating well with objective assessments of autonomic function. [45] [46] [47] [48] Some researchers have demonstrated good correlation between COMPASS-31 and physical measures such as heart-rate variability 14, 32 and autonomic function tests (including sudomotor, heart-rate response to Valsalva and deep breathing, head up tilt). 47, 48 However, other researchers have found no correlations between the COMPASS-31 and any physical measures of autonomic function. 45, 46, 49, 50 Although it is impossible to determine whether the COMPASS-31 scores reflect true autonomic dysfunction from our data, it is apparent that our sample reports high autonomic symptom burden. Our results are consistent with the previously published work examining autonomic function in Veterans with GWI using objective measures of autonomic function, 6, 13, 14 and support a more widespread use of objective autonomic testing in this population.
Subjects in our sample screened positive for depression at rates consistent with previous studies of clinical samples of Veterans with GWI; previous reports have ranged from 30% 51 to 60%. 52 Burden of, likely, PTSD was also consistent with previous reports from clinical samples, ranging from 33% 51 to 65%. 52 However, a positive anxiety screen was unexpectedly common in our sample compared with the literature, reported between 10% 53 and 59%. 15 Probably related, there were considerable differences in our sample for reported autonomic symptoms among subjects screening positive or negative for anxiety as detected by the BAI. There have been several papers where authors have discussed the limitations of the BAI, suggesting that the questionnaire may be capturing physical symptoms in populations with complex health conditions like postural orthostatic tachycardia syndrome 54 and rheumatoid arthritis. 34 In fact, the BAI manual itself states "The examiner should also closely inspect the BAI score for a pattern of symptom complaints. For example, a patient with predominantly somatic complaints may be suffering from an undetected medical condition" (page 6). 35 Because the BAI includes questions about physical symptoms (i.e., "feeling hot", indigestion or discomfort in the abdomen, "dizzy or lightheaded"), we looked more specifically at subscales of the BAI. The stronger correlation between the COMPASS-31 total score and the physical scale of the BAI (r = 0.638) compared with the cognitive scale (r = 0.275) suggests that the BAI is capturing some of the same physical complaints as the COMPASS-31. Our interpretation of these results is strengthened by the observation that the primary differences in those screening positive or negative for anxiety existed within the COMPASS domains of orthostatic and pupilomotor; the questions in the orthostatic domain largely overlapped with questions on the somatic scale of the BAI (see Table II ). Based on our results, we can recommend that providers not use the BAI to assess anxiety, rather use a different measure. For example, the Generalized Anxiety Disorder-7 item (GAD-7) scale is widely used in the VA, and it is an anxiety questionnaire that taps into nervousness, worry, trouble relaxing, restlessness, irritability, and foreboding without reliance on physiological symptoms that are nonspecific to anxiety and may instead capture other medical conditions. 55 In contrast to anxiety, when examining reported autonomic symptoms, there was no difference in the total COMPASS-31 scores between Veterans screening positive or negative for depression or PTSD. Similarly, when examining reported autonomic symptoms in Veterans screening positive or negative for PTSD, only the COMPASS-31 subdomain of pupilomotor was different between groups, with those screening positive for PTSD reporting more pupilomotor symptoms. The finding of more pupilomotor symptoms Note: All COMPASS-31 subdomains are presented as percent scores. Between groups, comparisons were made using t-tests. Statistical differences with p < 0.01 are bolded.
among individuals with PTSD compared with individuals without PTSD has been reported before in a Veteran population 56 and was attributed to an overall heightened sensitivity among those Veterans with PTSD. Interestingly, a recent study from Crane et al 57 examined 181 patients examined at a VA eye clinic with dry eye symptoms and found that irrespective of physical function, those Veterans who reported more ocular pain symptoms also experienced more nonocular pain symptoms and increased rates of PTSD and depression. These authors pointed toward possible neuroinflammatory processes as an explanation for their findings. A neuroinflammatory process has also been theorized as an underlying mechanism in GWI. 3, 6 These relationships warrant further investigation with quantitative, physiological measures in GWV and other populations.
Our study has several limitations to note, including its cross-sectional nature, lack of a control group, small study sample, selection bias of Veterans who were seen at our tertiary evaluation center, possible selection bias of subjects willing to complete questionnaires over the phone, the use of selfreported measures only, and multiple statistical comparisons. Due to the small sample size, we included in our sample all veterans who met criteria for either the CDC or Kansas case definitions. This introduces additional heterogeneity in our sample due to the presence of comorbid diagnoses, but given the increasing prevalence of chronic conditions in this population, we believe this approach improves the clinical relevance of our findings. Although we describe the medication usage in our sample, we were unable to systematically address the possible contribution of medications to report of autonomic symptoms. Despite these limitations, we feel that the study's strengths (which include the prospective nature of the COMPASS-31 administration, the use of validated instruments to capture self-reported symptoms, and the more rigorous threshold of p < 0.01 for statistical significance) contribute to the relevance and importance of our findings.
This was a case-series follow-up; a descriptive study of a clinical population. Certainly, it will be important to follow these findings with research investigating the objective physiological functioning of the autonomic nervous system in GW Veterans. In addition to research studies of autonomic dysfunction, clinicians might consider adding objective autonomic assessments (e.g., heart-rate response to deep breathing and Valsalva, sudomotor tests, and tilt table tests) to their evaluations to more objectively characterize GWI and potentially identify targets for intervention. Our findings also suggest that the BAI may be a suspect measure of anxiety in GWI, similar to other groups with chronic conditions. Based on our findings, we suggest providers use a different measure than the BAI to assess anxiety in Veterans with GWI. The results reported in this study enhance our understanding of the relationships between GWI, autonomic symptoms, and mental health conditions. 
